相关实验视频

Updated: Jan 9, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

在KMT2ArAML中进行向治疗

Ying Zhang¹, Yankun Yang¹, Yiwen Du¹

¹Department of Hematology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Hematology (Amsterdam, Netherlands)

|December 10, 2025

概括

针对性疗法对急性髓性白血病 (AML) 具有KMT2A重组 (KMT2Ar),一种耐化疗的亚型的有希望. 新的药物,包括脑膜抑制剂,正在进行研究,以改善患者对这种具有挑战性的白血病的治疗结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

患有KMT2A重组 (KMT2Ar) 的急性髓性白血病 (AML) 因化疗耐药性和预后不佳而构成重大临床挑战.
了解KMT2ArAML的分子复杂性对于开发有效的治疗策略至关重要.

研究的目的:

审查针对KMT2ArAML的向治疗的当前进展.
突出KMT2ArAML临床开发中的潜在治疗策略和药物.

主要方法:

综合审查研究,重点关注KMT2ArAML的分子特征.
对影响KMT2ArAML关键遗传和表观遗传机制的向药物的分析.
收集和检查有关药物机制,临床前发现和临床试验的数据.

主要成果:

新兴的向药物,如脑膜抑制剂,在KMT2ArAML中表现出令人鼓舞的临床活性.
针对DOT1L,BET和EZH2通路的抑制剂显示出有希望的临床前结果.
早期证据表明,组合疗法在克服耐药性方面可能优于单一疗法.

结论:

向治疗通过解决异常分子网络,为KMT2ArAML提供了一个有希望的新方向.
目前的疗法在很大程度上处于早期发展阶段,临床转化有限.
进一步的研究是必要的,以提高KMT2ArAML患者的治疗安全性和长期疗效.

关键词:

在AML,AML就是AML.在KMT2Ar中.阴抑制剂阴抑制剂有针对性的治疗.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...